Thymalin
A thymic polypeptide complex studied for immune restoration in aging research.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
Thymalin
COMPOUND
1 Research Goal
• Immune & Antimicrobial
Evidence Strength
3 articles sourced
Knowledge Graph
(4 connections)Research Evidence
(3)Thymalin: Thymic Peptide Immunomodulation — Clinical and Translational Evidence
Thymalin is a thymus-derived peptide preparation used clinically in several countries for immunomodulation. This review summarizes the translational and clinical evidence supporting its use in immune restoration.
Peptide Synergy: Longevity and Mitochondrial Optimization
Evidence-based review of longevity peptide synergy, examining mitochondrial function, telomerase activity, and cellular senescence mechanisms.
Peptide Synergy: Immune System Modulation
Evidence-based review of immune peptide synergy, examining thymic function, antimicrobial defense, and cytokine modulation.
Overview
Thymalin is a thymic polypeptide complex originally isolated from calf thymus tissue, studied extensively in Russian medical research for its immune-restoring properties. As a thymus-derived peptide, Thymalin belongs to the class of thymic peptides that regulate T-cell development and immune function. Research has explored its potential in age-related immune decline, chronic infections, and as an immune system modulator.
Mechanism of Action
Thymalin acts on the thymus gland and T-lymphocyte system, promoting the maturation, differentiation, and functional activity of T lymphocytes. It enhances the production of thymic hormones and supports the thymus's role in T-cell education and selection. By modulating T-cell function, Thymalin influences both cellular and humoral immune responses. Research suggests it may also influence the production of cytokines and the balance between T-helper subsets, contributing to its broad immunomodulatory effects.
Research Highlights
Clinical studies in Russia have demonstrated Thymalin's efficacy in improving immune parameters in elderly patients, with improvements in T-cell counts, natural killer cell activity, and reduced infection rates. Research has explored its potential in chronic infections, autoimmune conditions, and as an adjunct in cancer treatment. Studies have shown benefits in post-surgical immune recovery and in patients with immunodeficiency conditions. Research has also investigated its potential in combination with other thymic peptides for comprehensive immune restoration in aging.
Dosage & Administration
In Russian clinical practice, Thymalin has been administered via subcutaneous or intramuscular injection at doses of 5-10 mg per day, typically over courses of 5-10 days. For research use only (RUO).
Safety Profile
Thymalin has been used clinically in Russia with a reported favorable safety profile. Adverse effects are rare and mild, including occasional injection site reactions. Long-term safety data is available from Russian clinical experience. Not approved by the FDA in the United States.
References
Khavinson VKh, et al. Thymalin and immune function. Bull Exp Biol Med. 2003. Anisimov VN, et al. Thymic peptides and aging. Biogerontology. 2005. Russian clinical literature on thymic peptides. All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(3)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
View full comparison matrixComputational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.